Indium-111 clinical trials
How each study uses Indium-111 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Indium-111 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 6
Radboud University Medical Center (5) · Ratio Therapeutics, Inc. (1) · Tufts Medical Center (1)
Often tested with
Tested in the same studies.
Imp-288 (1) · Lutetium-177 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Indium-111.
- Dec 2026TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.Early Phase 1 · Radboud University Medical Center
Studies
Open first, then newest update. How each study uses Indium-111 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.RecruitingEarly Phase 1Radboud University Medical CenterNCT07009184Written as [111In]In-DOTA-TCO-trastuzumab
- Multimodal Imaging in Rectal Cancer & Pancreatic CancerNot yet recruitingPhase 1/2Radboud University Medical CenterNCT06395337Written as [111In]In-DOTA-ANTI-CEA antibody injection
- Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate CancerCompletedEarly Phase 1Ratio Therapeutics, Inc.NCT05773703Written as PSMA-Targeted [In-111]-Labeled Trillium Compound
- Intraoperative Dual-modality Imaging in Renal Cell CarcinomaStatus unknownPhase 1Radboud University Medical CenterNCT02497599Written as Indium-111-DOTA-Girentuximab-IRDye800CW
- Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal OriginStatus unknownPhase 1/2Radboud University Medical CenterNCT03699332Written as Indium-111-DOTA-Labetuzumab-IRDye800CW injection
- Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple MyelomaTerminatedPhase 2Tufts Medical CenterNCT01207765Written as indium-111-ibritumomab tiuxetan
- Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal CancerCompletedPhase 1Radboud University Medical CenterNCT00860860Written as IMP-288 labeled with In111 and Lu177
Given beside what is tested · 5 — Indium-111 is usual care or a partner of the new treatment
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingPhase 1AstraZenecaNCT06147037Written as [111In]-FPI-2107
- Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLCTerminatedPhase 1AstraZenecaNCT07500987Written as [111In]-FPI-2107
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedPhase 1Fusion Pharmaceuticals Inc.NCT03746431Written as [111In]-FPI-1547 Injection
- S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaCompletedPhase 2SWOG Cancer Research NetworkNCT00070018Written as Indium-111 ibritumomab tiuxetan
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine TumorsTerminatedPhase 1/2Insel Gruppe AG, University Hospital BernNCT02078843Written as Indium-111-Octreoscan (standard test)
Codes
What other systems call Indium-111 · ClinicalTrials.gg INT000643
- MeSH (NLM) C000615551Indium-111One source NLM
- UNII (FDA) E9NGC49E0TINDIUM IN-111Confirmed FDA, NLM, Wikidata
- RxNorm 90540Confirmed FDA, Wikidata
- Wikidata Q6025171indium-111Confirmed FDA, NLM, Wikidata
- DrugBank DB11916One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615551 | Indium-111 | One source NLM |
| UNII (FDA) | E9NGC49E0T | INDIUM IN-111 | Confirmed FDA, NLM, Wikidata |
| RxNorm | 90540 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6025171 | indium-111 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB11916 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.